SCHEMBL6478631

SCHEMBL6478631

Cc1cccc(CNC(=O)C=Cc2c(-c3ccccc3)n(C)c3ccccc23)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.48
LMNA P02545 1/20 0.48
ASAH1 Q13510 2/20 0.46
KMT2A Q03164 1/20 0.45
HDAC1 Q13547 3/20 0.43
HDAC8 Q9BY41 3/20 0.43
HDAC6 Q9UBN7 3/20 0.43
MMP1 P03956 2/20 0.43
MMP2 P08253 2/20 0.43
MMP9 P14780 2/20 0.43
MAPT P10636 3/20 0.43
NPC1 O15118 2/20 0.43
RAB9A P51151 2/20 0.43
KDM4E B2RXH2 1/20 0.43
RXFP1 Q9HBX9 1/20 0.43
SMN1; SMN2 Q16637 3/20 0.42
HTT P42858 1/20 0.41
ATM Q13315 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6478627 1.00 ALDH1A1 (0.48) ALDH1A1LMNAASAH1KMT2AHDAC1
SCHEMBL6487521 0.90 ALDH1A1 (0.46) ALDH1A1LMNAMMP1MMP2MMP9
SCHEMBL6487526 0.90 ALDH1A1 (0.46) ALDH1A1LMNAMMP1MMP2MMP9
SCHEMBL6486265 0.89 KMT2A (0.55) ALDH1A1LMNAKMT2AHDAC1MMP1
SCHEMBL6486271 0.89 KMT2A (0.55) ALDH1A1LMNAKMT2AHDAC1MMP1
SCHEMBL6488724 0.84 GAA (0.53) ALDH1A1LMNAASAH1KMT2AMAPT
SCHEMBL6488719 0.84 GAA (0.53) ALDH1A1LMNAASAH1KMT2AMAPT
SCHEMBL6487393 0.84 KMT2A (0.50) ALDH1A1LMNAKMT2AMMP1MMP2
SCHEMBL6487398 0.84 KMT2A (0.50) ALDH1A1LMNAKMT2AMMP1MMP2
SCHEMBL6478467 0.82 MEN1 (0.56) ALDH1A1LMNAKMT2AMAPTNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050014942-A1 Transforming growth factor inhibitor; controllign cell differentiation, cell proliferation NIPPON SHINYAKU CO., LTD. (JP) 2005-01-20 US disclosed
EP-1452525-A1 AMIDE DERIVATIVES AND DRUGS Nippon Shinyaku Co., Ltd. (JP) 2004-09-01 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050014942-A1 Transforming growth factor inhibitor; controllign cell differentiation, cell proliferation TGFBR1, TGFBR2, TGFB1 ALDH1A1 2521/4885LMNA 2502/4885ASAH1 3672/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.